tbuckley/cabot-search huggingface dataset:
Strain of Multidrug-Resistant <i>Salmonella</i> Newport Remains Linked to Travel to Mexico and U.S. Beef Products — United States, 2021–2022
Authors: Laura Ford, Zachary Ellison, Colin Schwensohn, Isabel Griffin, Meseret G. Birhane, Andrea Cote, Gamola Z. Fortenberry, Selam Tecle, Jeffrey Higa, Samantha Spencer, Brianna Patton, Jaimini Patel, Julie Dow, Azarnoush Maroufi, Amy Robbins, Danielle Donovan, Conor Fitzgerald, Sierra Burrell, Beth Tolar, Jason P. Folster, Laura A. Cooley, Louise K. Francois Watkins
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

In 2016, CDC identified a multidrug-resistant (MDR) strain of Salmonella enterica serotype Newport that is now monitored as a persisting strain (REPJJP01). Isolates have been obtained from U.S. residents in all 50 states and the District of Columbia, linked to travel to Mexico, consumption of beef products obtained in the United States, or cheese obtained in Mexico. In 2021, the number of isolates of this strain approximately doubled compared with the 2018-2020 baseline and remained high in 2022. During January 1, 2021- December 31, 2022, a total of 1,308 isolates were obtained from patients, cattle, and sheep; 86% were MDR, most with decreased susceptibility to azithromycin. Approximately one half of patients were Hispanic or Latino; nearly one half reported travel to Mexico during the month preceding illness, and one third were hospitalized. Two multistate outbreak investigations implicated beef products obtained in the United States. This highly resistant strain might spread through travelers, animals, imported foods, domestic foods, or other sources. Isolates from domestic and imported cattle slaughtered in the United States suggests a possible source of contamination. Safe food and drink consumption practices while traveling and interventions across the food production chain to ensure beef safety are necessary in preventing illness.
Declines in Influenza Vaccination Coverage Among Health Care Personnel in Acute Care Hospitals During the COVID-19 Pandemic — United States, 2017–2023
Authors: Hoody Lymon, Lu Meng, Hannah E. Reses, Kira Barbre, Heather Dubendris, Shanjeeda Shafi, Ryan Wiegand, Gnanendra Reddy Tugu Yagama Reddy, Austin Woods, David T. Kuhar, Matthew J. Stuckey, Megan C. Lindley, Lori Haas, Iram Qureshi, Emily Wong, Andrea Benin, Jeneita M. Bell
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

Health care personnel (HCP) are recommended to receive annual vaccination against influenza to reduce influenza-related morbidity and mortality. Every year, acute care hospitals report receipt of influenza vaccination among HCP to CDC's National Healthcare Safety Network (NHSN). This analysis used NHSN data to describe changes in influenza vaccination coverage among HCP in acute care hospitals before and during the COVID-19 pandemic. Influenza vaccination among HCP increased during the prepandemic period from 88.6% during 2017-18 to 90.7% during 2019-20. During the COVID-19 pandemic, the percentage of HCP vaccinated against influenza decreased to 85.9% in 2020-21 and 81.1% in 2022-23. Additional efforts are needed to implement evidence-based strategies to increase vaccination coverage among HCP and to identify factors associated with recent declines in influenza vaccination coverage.
Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
Authors: Susan L. Hills, Katherine A. Poehling, Wilbur H. Chen, J. Erin Staples
Journal: MMWR Recommendations and Reports (2023)

Ixodes species ticks but can also be acquired less frequently by alimentary transmission. Other rare modes of transmission include through breastfeeding, blood transfusion, solid organ transplantation, and slaughtering of viremic animals. TBE virus can cause acute neurologic disease, which usually results in hospitalization, often permanent neurologic or cognitive sequelae, and sometimes death. TBE virus infection is a risk for certain travelers and for laboratory workers who work with the virus. In August 2021, the Food and Drug Administration approved Ticovac TBE vaccine for use among persons aged ≥1 year. This report summarizes the epidemiology of and risks for infection with TBE virus, provides information on the immunogenicity and safety of TBE vaccine, and summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of TBE vaccine among U.S. travelers and laboratory workers.
Progress Toward Eradication of Dracunculiasis — Worldwide, January 2022–June 2023
Authors: Donald R. Hopkins, Adam J. Weiss, Sarah Yerian, Sarah G.H. Sapp, Vitaliano A. Cama
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

The effort to eradicate Dracunculus medinensis, the etiologic agent of dracunculiasis, or Guinea worm disease, commenced at CDC in 1980. In 1986, with an estimated 3.5 million cases worldwide in 20 African and Asian countries, the World Health Assembly called for dracunculiasis elimination. The Guinea Worm Eradication Program (GWEP) was established to help countries with endemic dracunculiasis reach this goal. GWEP is led by The Carter Center and supported by partners that include the World Health Organization, UNICEF, and CDC. In 2012, D. medinensis infections were unexpectedly confirmed in Chadian dogs, and since then, infections in dogs, cats, and baboons have posed a new challenge for GWEP, as have ongoing civil unrest and insecurity in some areas. By 2022, dracunculiasis was endemic in five countries (Angola, Chad, Ethiopia, Mali, and South Sudan), with only 13 human cases identified, the lowest yearly total ever reported. Animal infections, however, were not declining at the same rate: 686 animal infections were reported in 2022, including 606 (88%) in dogs in Chad. Despite these unanticipated challenges as well as the COVID-19 pandemic, countries appear close to reaching the eradication goal. GWEP will continue working with country programs to address animal infections, civil unrest, and insecurity, that challenge the eradication of Guinea worm.
Coverage with Selected Vaccines and Exemption from School Vaccine Requirements Among Children in Kindergarten — United States, 2022–23 School Year
Authors: Ranee Seither, Oyindamola Bidemi Yusuf, Devon Dramann, Kayla Calhoun, Agnes Mugerwa-Kasujja, Cynthia L. Knighton
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

U.S. states and local jurisdictions set vaccination requirements for school attendance and conditions and procedures for exemptions from these requirements. States annually report data to CDC on the number of children in kindergarten who meet, are exempt from, or are in the process of meeting requirements. National- and state-level estimates for complete vaccination with measles, mumps, and rubella vaccine (MMR); diphtheria, tetanus, and acellular pertussis vaccine (DTaP); poliovirus vaccine (polio); and varicella vaccine (VAR); exemptions from vaccination; and legally allowed kindergarten attendance while meeting requirements were based on data reported by 49 states and the District of Columbia (DC) for the 2022-23 school year. This kindergarten class became age-eligible to complete most state-required vaccinations during the COVID-19 pandemic. National coverage remained near 93% for all vaccines; exemptions were low but increased to 3%, compared with those during the 2021-22 school year (2.6%). At the state level, coverage with MMR, DTaP, polio, and VAR decreased in 29, 31, 28, and 25 states, respectively, compared with coverage during the 2021-22 school year. Exemptions increased in 40 states and DC, with 10 states reporting an exemption from at least one vaccine for >5% of kindergartners. Schools and providers should work to ensure that students are vaccinated before school entry, such as during the enrollment process, which is often several months before school starts. State and local provisional enrollment periods that allow students to attend school while on a catch-up schedule also provide the opportunity to fully vaccinate students and to prevent nonmedical exemptions resulting from lingering undervaccination due to COVID-19 pandemic-related barriers to vaccination, such as reduced access to vaccination appointments.
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
Authors: William C. Chen, Abrar Choudhury, Mark W. Youngblood, Mei-Yin C. Polley, Calixto-Hope G. Lucas, Kanish Mirchia, Sybren L. N. Maas, Abigail K. Suwala, Minhee Won, James C. Bayley, Akdes S. Harmanci, Arif O. Harmanci, Tiemo J. Klisch, Minh P. Nguyen, Harish N. Vasudevan, Kathleen McCortney, Theresa J. Yu, Varun Bhave, Tai-Chung Lam, Jenny Kan-Suen Pu, Lai-Fung Li, Gilberto Ka-Kit Leung, Jason W. Chan, Haley K. Perlow, Joshua D. Palmer, Christine Haberler, Anna S. Berghoff, Matthias Preusser, Theodore P. Nicolaides, Christian Mawrin, Sameer Agnihotri, Adam Resnick, Brian R. Rood, Jessica Chew, Jacob S. Young, Lauren Boreta, Steve E. Braunstein, Jessica Schulte, Nicholas Butowski, Sandro Santagata, David Spetzler, Nancy Ann Oberheim Bush, Javier E. Villanueva-Meyer, James P. Chandler, David A. Solomon, C. Leland Rogers, Stephanie L. Pugh, Minesh P. Mehta, Penny K. Sneed, Mitchel S. Berger, Craig M. Horbinski, Michael W. McDermott, Arie Perry, Wenya Linda Bi, Akash J. Patel, Felix Sahm, Stephen T. Magill, David R. Raleigh
Journal: Nature Medicine (2023)
Culture Media Tweak Makes Heartier CAR T Cells
Journal: Cancer Discovery (2023)

Abstract Supplementing growth media with a naturally occurring nucleoside has been found to enhance the antitumor and proliferative capabilities of CAR T-cell therapies. Research presented at the Society for Immunotherapy of Cancer's Annual Meeting indicates that inosine triggers metabolic reprogramming within the cells, resulting in a more stem-like state that helps counteract exhaustion.
Advancing neural regeneration via adaptable hydrogels: Enriched with Mg2+ and silk fibroin to facilitate endogenous cell infiltration and macrophage polarization
Authors: Yisheng Gao, Yingyu Wang, Jianye Zhang, Miao Zhang, Chaolun Dai, Yang Zhang, Luzhong Zhang, Liming Bian, Yumin Yang, Kunyu Zhang, Yahong Zhao
Journal: Bioactive Materials (2023)

Peripheral nerve injury is a complex and challenging medical condition due to the limited ability of nerves to regenerate, resulting in the loss of both sensory and motor function. Hydrogels have emerged as a promising biomaterial for promoting peripheral nerve regeneration, while conventional hydrogels are generally unable to support endogenous cell infiltration due to limited network dynamics, thereby compromising the therapeutic outcomes. Herein, we present a cell adaptable hydrogel containing a tissue-mimetic silk fibroin network and a dynamically crosslinked bisphosphonated-alginate network. The dynamic network of this hydrogel can respond to cell-generated forces to undergo the cell-mediated reorganization, thereby effectively facilitating the rapid infiltration of Schwann cells and macrophages, as well as the ingrowth of axons. We further show that the magnesium ions released from the hydrogel not only promote neurite outgrowth but also regulate the polarization of macrophages in a sequential manner, contributing to the formation of a regenerative microenvironment. Therefore, this hydrogel effectively prevents muscle atrophy and promotes the regeneration and functional recovery of nerve defects of up to 10 mm within 8 weeks. The findings from this study demonstrate that adaptable hydrogels are promising inductive biomaterials for enhancing the therapeutic outcomes of peripheral nerve injury treatments.
Author Correction: Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants
Authors: Nicole L Welch, Meilin Zhu, Catherine Hua, Juliane Weller, Marzieh Ezzaty Mirhashemi, Tien G Nguyen, Sreekar Mantena, Matthew R Bauer, Bennett M Shaw, Cheri M Ackerman, Sri Gowtham Thakku, Megan W Tse, Jared Kehe, Marie-Martine Uwera, Jacqueline S Eversley, Derek A Bielwaski, Graham McGrath, Joseph Braidt, Jeremy Johnson, Felecia Cerrato, Gage K Moreno, Lydia A Krasilnikova, Brittany A Petros, Gabrielle L Gionet, Ewa King, Richard C Huard, Samantha K Jalbert, Michael L Cleary, Nicholas A Fitzgerald, Stacey B Gabriel, Glen R Gallagher, Sandra C Smole, Lawrence C Madoff, Catherine M Brown, Matthew W Keller, Malania M Wilson, Marie K Kirby, John R Barnes, Daniel J Park, Katherine J Siddle, Christian T Happi, Deborah T Hung, Michael Springer, Bronwyn L MacInnis, Jacob E Lemieux, Eric Rosenberg, John A Branda, Paul C Blainey, Pardis C Sabeti, Cameron Myhrvold
Journal: Nature Medicine (2023)
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized <scp>Open‐Label</scp> Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission
Authors: Joanna Kedra, Philippe Dieudé, Caroline Giboin, Hubert Marotte, Carine Salliot, Thierry Schaeverbeke, Aleth Perdriger, Martin Soubrier, Jacques Morel, Arnaud Constantin, Emmanuelle Dernis, Valérie Royant, Jean‐Hugues Salmon, Thao Pham, Jacques‐Eric Gottenberg, Edouard Pertuiset, Maxime Dougados, Valérie Devauchelle‐Pensec, Philippe Gaudin, Grégoire Cormier, Philippe Goupille, Xavier Mariette, Francis Berenbaum, Didier Alcaix, Sid‐Ahmed Rouidi, Jean‐Marie Berthelot, Agnès Monnier, Christine Piroth, Frédéric Lioté, Vincent Goëb, Cécile Gaujoux‐Viala, Isabelle Chary‐Valckenaere, David Hajage, Florence Tubach, Bruno Fautrel
Journal: Arthritis & Rheumatology (2023)

We assess the clinical and structural impact at two years of progressively spacing tocilizumab (TCZ) or abatacept (ABA) injections versus maintenance at full dose in patients with rheumatoid arthritis in sustained remission.
Harnessing Human Placental Membrane‐Derived Bioinks: Characterization and Applications in Bioprinting and Vasculogenesis
Authors: Léo Comperat, Lise Chagot, Sarah Massot, Marie‐Laure Stachowicz, Nathalie Dusserre, Chantal Médina, Théo Desigaux, Jean‐William Dupuy, Jean‐Christophe Fricain, Hugo Oliveira
Journal: Advanced Healthcare Materials (2023)

Abstract Bioprinting applications in the clinical field generate great interest, but developing suitable biomaterial inks for medical settings is a challenge. Placental tissues offer a promising solution due to their abundance, stability, and status as medical waste. They contain basement membrane components, have a clinical history, and support angiogenesis. This study formulates bioinks from two placental tissues, amnion (AM) and chorion (CHO), and compares their unique extracellular matrix (ECM) and growth factor compositions. Rheological properties of the bioinks are evaluated for bioprinting and maturation of human endothelial cells. Both AM and Cho‐derived bioinks sustained human endothelial cell viability, proliferation, and maturation, promoting optimal vasculogenesis. These bioinks derived from human sources have significant potential for tissue engineering applications, particularly in supporting vasculogenesis. This research contributes to the advancement of tissue engineering and regenerative medicine, bringing everyone closer to clinically viable bioprinting solutions using placental tissues as valuable biomaterials.
Genetic data do not provide evidence that lower sclerostin is associated with increased risk of atherosclerosis: comment on the article by Zheng <i>et al</i>
Authors: James R. Staley, Olga Giannakopoulou, Gill Holdsworth, Martin Armstrong
Journal: Arthritis & Rheumatology (2023)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
Authors: Narendranath Epperla, Lei Feng, Nirav N Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M Stephens, Catherine J Lee, Thomas Ollila, Geoffrey Shouse, Alexey V Danilov, Kevin A David, Pallawi Torka, Hamza Hashmi, Brian Hess, Stefan K Barta, Jason T Romancik, Jonathon B Cohen, Kaitlin Annunzio, Adam S Kittai, John Reneau, Joanna Zurko, Imran A Nizamuddin, Jane N Winter, Leo I Gordon, Shuo Ma, Romil Patel, Loretta Nastoupil, Sairah Ahmed, Reem Karmali
Journal: Journal of Hematology & Oncology (2023)

Abstract Chimeric antigen receptor T-cell therapy (CAR-T) has been successful in treating relapsed/refractory B-cell lymphomas. However, its role in the treatment of diseases involving the central nervous system (CNS) is not well studied. We performed a multicenter retrospective cohort study to evaluate the outcomes of patients with secondary CNS lymphoma (SCNSL) who received CAR-T. Eligibility required active CNSL at the time of apheresis. The objectives included evaluation of overall survival (OS), progression-free survival (PFS), identification of predictors of complete response (CR) post-CAR-T, and assessment of risk factors for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Sixty-one patients were included in the analysis. The overall response rate was 68% with a CR rate of 57%. In the multivariable analysis, patients who experienced any grade CRS had higher odds of achieving CR (OR = 3.9, 95% CI = 1.01–15.39, p = 0.047). The median PFS was 3.3 months (95% CI = 2.6–6.0 months) with 6- and 12-month PFS rates of 35% and 16%, respectively. The median OS was 7.6 months (95% CI = 5.0–13.5 months) with 6- and 12-month OS rates of 59% and 41%, respectively. Any grade CRS and ICANS were 70% (n = 43) and 57% (n = 34), respectively with grade ≥ 3 CRS and ICANS rates of 16% and 44%. Factors associated with increased risk of CRS and ICANS included receiving axi-cel or having leptomeningeal ± parenchymal + CNS involvement, respectively. Despite achieving high response rates, most patients experience early relapse or death following CAR-T in SCNSL. The current study provides a benchmark for future trials exploring novel therapeutic options in SCNSL.
Isolation and Enrichment of Extracellular Vesicles with Double‐Positive Membrane Protein for Subsequent Biological Studies
Authors: Chunchen Liu, Huixian Lin, Haiyang Yu, Xueying Mai, Weilun Pan, Jingyun Guo, Tong Liao, Junjie Feng, Ye Zhang, Bo Situ, Lei Zheng, Bo Li
Journal: Advanced Healthcare Materials (2023)

The isolation and enrichment of specific extracellular vesicle (EV) subpopulations are essential in the context of precision medicine. However, the current methods predominantly rely on a single-positive marker and are susceptible to interference from soluble proteins or impurities. This limitation represents a significant obstacle to the widespread application of EVs in biological research. Herein, a novel approach that utilizes proximity ligation assay (PLA) and DNA-RNA hybridization are proposed to facilitate the binding of two proteins on the EV membrane in advance enabling the isolation and enrichment of intact EVs with double-positive membrane proteins followed by using functionalized magnetic beads for capture and enzymatic cleavage for isolated EVs release. The isolated subpopulations of EVs can be further utilized for cellular uptake studies, high-throughput small RNA sequencing, and breast cancer diagnosis. Hence, developing and implementing a specialized system for isolating and enriching a specific subpopulation of EVs can enhance basic and clinical research in this field.
Gut microbiota regulates postprandial GLP-1 response via ileal bile acid-TGR5 signaling
Authors: Qiaoling Wang, Huibin Lin, Chongrong Shen, Minchun Zhang, Xingyu Wang, Miaomiao Yuan, Mingyang Yuan, Sheng Jia, Zhiwen Cao, Chao Wu, Banru Chen, Aibo Gao, Yufang Bi, Guang Ning, Weiqing Wang, Jiqiu Wang, Ruixin Liu
Journal: Gut Microbes (2023)

The gut microbiota interacts with intestinal epithelial cells through microbial metabolites to regulate the release of gut hormones. We investigated whether the gut microbiota affects the postprandial glucagon-like peptide-1 (GLP-1) response using antibiotic-treated mice and germ-free mice. Gut microbiome depletion completely abolished postprandial GLP-1 response in the circulation and ileum in a lipid tolerance test. Microbiome depletion did not influence the GLP-1 secretory function of primary ileal cells in response to stimulators in vitro, but dramatically changed the postprandial dynamics of endogenous bile acids, particularly ω-muricholic acid (ωMCA) and hyocholic acid (HCA). The bile acid receptor Takeda G protein-coupled receptor 5 (TGR5) but not farnesoid X receptor (FXR), participated in the regulation of postprandial GLP-1 response in the circulation and ileum, and ωMCA or HCA stimulated GLP-1 secretion via TGR5. Finally, fecal microbiota transplantation or ωMCA and HCA supplementation restored postprandial GLP-1 response. In conclusion, gut microbiota is indispensable for maintaining the postprandial GLP-1 response specifically in the ileum, and bile acid (ωMCA and HCA)-TGR5 signaling is involved in this process. This study helps to understand the essential interplay between the gut microbiota and host in regulating postprandial GLP-1 response and opens the foundation for new therapeutic targets.
ERS “CONNECT” Clinical Research Collaboration – moving multiple digital innovations towards connected respiratory care: addressing the over-arching challenges of whole systems implementation
Authors: Job F.M. van Boven, David Drummond, Amy H.Y. Chan, Mark Hew, Chi Yan Hui, Ireti Adejumo, Isaac Cano, Kjeld Hansen, Vitalii Poberezhets, Richard W. Costello, Hilary Pinnock
Journal: European Respiratory Journal (2023)

In summer 2023, the European Respiratory Society (ERS) welcomed a new Clinical Research Collaboration (CRC) focused on implementation of digital respiratory health: " CONNECT" – moving multiple digital innovations towards connected respiratory care: addressing the over-arching challenges of whole systems implementation . Historically, CRCs aim to foster research collaboration and stimulate joint grant applications around single respiratory diseases [1, 2]. In an innovative approach, "CONNECT" spans all respiratory diseases and ERS Assemblies, thereby not only connecting humans and digital devices, and patients with healthcare professionals, but also linking existing CRCs within the ERS. In this editorial, we introduce the rationale, aims and working groups of "CONNECT". The new ERS Clinical Research Collaboration "CONNECT" aims to accelerate implementation of digital respiratory health technology <https://bit.ly/45FtFmS> The authors would like to thank all people that have expressed interest in CONNECT and already joined one or more working groups. Also, we would like to acknowledge the input of the expert advisory group (Arzu Yorgancıoğlu, David Price, Anita Simonds, Jerry Krishnan, Dennis Falzon and Barbara Hoffman) during the design of this CRC.
Unravelling the expanding role of FGF10 signalling in lung homeostasis and maintenance
Authors: Enid R. Neptune, Wellington V. Cardoso
Journal: European Respiratory Journal (2023)

<h3>Tweetable abstract</h3> <b>Altered FGF10 signalling contributes to experimental emphysema with pulmonary hypertension and is a promising therapeutic target for clinical exploration</b>https://bit.ly/3S0co4N
Children and the European Respiratory Society: from silos to synergies
Authors: Monika Gappa, Andrew Bush, Refika Hamutcu Ersu, Manuel E. Soto-Martinez, Alexander Moeller, Mariëlle W. Pijnenburg, Varinder Singh, Susanne J.H. Vijverberg, Heather J. Zar
Journal: European Respiratory Journal (2023)

<h3>Tweetable abstract</h3> <b>Awareness of child health and its importance for adult lung health should increase; paediatric perspectives should be part of all ERS activities. Disparities between and within countries need to be addressed, as well as a relative lack of clinical trials.</b> https://bit.ly/3ROa1Sz